User:Mr. Ibrahem/Insulin aspart
 | |
| Clinical data | |
|---|---|
| Trade names | NovoLog, NovoRapid, Fiasp, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a605013 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous, intravenous |
| Drug class | Insulin (short acting) |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Onset of action | ~ 2 hrs (max)[2] |
| Duration of action | ~ 4 hrs[2] |
| Chemical and physical data | |
| Formula | C256H381N65O79S6 |
| Molar mass | 5825.60 g·mol−1 |
  (what is this?) (verify) | |
Insulin aspart, sold under the brand name Novolog among others, is a type of manufactured insulin used to treat type 1 and type 2 diabetes.[2] Typically it is taken just before eating.[2] It is generally used by injection under the skin but may also be used by injection into a vein.[2] Maximum effect occurs after about 1–3 hours and lasts for 3–5 hours.[2] Generally a longer-acting insulin like NPH is also needed.[2]
Common side effects include low blood sugar, allergic reactions, itchiness, and pain at the site of injection.[2] Other serious side effects may include low blood potassium.[2] Use in pregnancy and breastfeeding is generally safe.[1] It works the same as human insulin by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver.[2] It is a manufactured form of human insulin; where a single amino acid has been changed, specifically a proline with an aspartic acid at the B28 position.[4]
Insulin aspart was approved for medical use in the United States in 2000.[2] In the United Kingdom it costs the NHS about £1.89 per 100 units as of 2019.[5] In the United States the wholesale cost of this amount is about US$30.00.[6] In 2017, it was the 56th most prescribed medication in the United States, with more than 14 million prescriptions.[7][8] Manufacturing involves yeast, which have had the gene for insulin aspart put into their genome.[9] This yeast then makes the insulin, which is harvested from the bioreactor.[10]
References[edit]
- ^ a b c "Insulin aspart Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ a b c d e f g h i j k l m "Insulin Aspart Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 8 August 2020. Retrieved 6 September 2020.
- ^ Turner JR (2010). New Drug Development: An Introduction to Clinical Trials: Second Edition. Springer Science & Business Media. p. 32. ISBN 9781441964182. Archived from the original on 2019-03-06. Retrieved 2019-03-06.
- ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 697. ISBN 9780857113382.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
- ^ "Insulin Aspart - Drug Usage Statistics". ClinCalc. Archived from the original on 12 April 2020. Retrieved 11 April 2020.
- ^ Banga, Ajay K. (2005). Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, Second Edition. CRC Press. p. 13. ISBN 9781420039832. Archived from the original on 2019-03-06. Retrieved 2019-03-06.
- ^ Schmid, Rolf D.; Schmidt-Dannert, Claudia (2016). Biotechnology: An Illustrated Primer. John Wiley & Sons. p. 222. ISBN 9783527677566. Archived from the original on 2019-03-06. Retrieved 2019-03-06.